The current study was undertaken to investigate the efficacy and safety of erlotinib versus pemetrexed as second-line therapy for patients with advanced epidermal growth factor receptor ( EGFR ) wild-type and EGFR fluorescence in situ hybridization ( FISH ) - positive lung adenocarcinoma .